Experimental Approaches to Identify Selective Picomolar Inhibitors for Carbonic Anhydrase IX

Background: Carbonic anhydrases (CAs) regulate pH homeostasis via the reversible hydration of CO2, thereby emerging as essential enzymes for many vital functions. Among 12 catalytically active CA isoforms in humans, CA IX has become a relevant therapeutic target because of its role in cancer progression. Only two CA IX inhibitors have entered clinical trials, mostly due to low affinity and selectivity properties. Objective: The current review presents the design, development, and identification of the selective nano-to picomolar CA IX inhibitors VD11-4-2, VR16-09, and VD12-09. Methods and Results: Compounds were selected from our database, composed of over 400 benzensulfonamides, synthesized at our laboratory, and tested for their binding to 12 human CAs. Here we discuss the CA CO2 hydratase activity/inhibition assay and several biophysical techniques, such as fluorescent thermal shift assay and isothermal titration calorimetry, highlighting their contribution to the analysis of compound affinity and structure-activity relationships. To obtain sufficient amounts of recombinant CAs for inhibitor screening, several gene cloning and protein purification strategies are presented, including site-directed CA mutants, heterologous CAs from Xenopus oocytes, and native endogenous CAs. The cancer cell-based methods, such as clonogenicity, extracellular acidification, and mass spectrometric gas-analysis are reviewed, confirming nanomolar activities of lead inhibitors in intact cancer cells. Conclusions: Novel CA IX inhibitors are promising derivatives for in vivo explorations. Furthermore, the simultaneous targeting of several proteins involved in proton flux upon tumor acidosis and the disruption of transport metabolons might improve cancer management. Superscript/Subscript Available

Automated summary

This review presents the design, development, and identification of selective nano-to picomolar CA IX inhibitors VD11-4-2, VR16-09, and VD12-09. Various methods and results were discussed, including compound binding, biophysical techniques, protein cloning and purification strategies, and cancer cell-based assays which confirmed nanomolar activities of lead inhibitors. Novel CA IX inhibitors show promise for in vivo exploration and targeting multiple proteins involved in tumor acidosis may improve cancer management.